Larry E Humes, Sumitrajit Dhar, Mary Meskan, Anna Pitman, Jasleen Singh
{"title":"A Multisite Randomized Controlled Trial Comparing the Effectiveness of Two Self-Fit Methods to the Best-Practices Method of Hearing Aid Fitting.","authors":"Larry E Humes, Sumitrajit Dhar, Mary Meskan, Anna Pitman, Jasleen Singh","doi":"10.1044/2024_JSLHR-24-00423","DOIUrl":null,"url":null,"abstract":"<p><strong>Trial design: </strong>This is a randomized multisite noninferiority comparative-effectiveness clinical trial with three parallel branches comparing a best-practices audiologist-fit method to two experimental self-fit (person-fit) methods. Outcomes were measured at 6 weeks and 6 months post-fit.</p><p><strong>Method: </strong>Participants: Five hundred eighty-four participants met the following inclusion criteria and enrolled: (a) age between 50 and 79 years; (b) never used or tried hearing aids previously; (c) can speak, read, and understand English well; (d) willing to purchase the study hearing aids for $650/pair; (e) no diagnosis of a memory or cognitive impairment; (f) 25-item Hearing Handicap Inventory for the Elderly (HHIE) score > 4; (g) Montreal Cognitive Assessment score ≥ 23; and (h) not excluded due to specific audiometric criteria. The audiometric exclusion criteria, based on air-conduction pure-tone thresholds, were as follows: (a) thresholds at all frequencies (250-8000 Hz) < 20 dB HL, for both ears (no hearing loss); (b) pure-tone average for 500, 1000, 2000, and 4000 Hz (PTA4) in the better ear > 50 dB HL (greater than moderate hearing loss); and (c) interaural difference > 20 dB at three or more frequencies or ≥ 40 dB at 500 or 1000 Hz. Interventions: Three groups received the same hearing aids fitted either by an audiologist using best practices (Group AB) or by themselves using one of two efficacious self-fit methods (Groups CD and EF). Objectives: The effectiveness of each of the self-fit methods, CD and EF, was hypothesized to be noninferior to the professional-fit method, AB. Outcomes: The primary outcome measure was the global score from the Profile of Hearing Aid Benefit (PHAB), and the secondary outcome measure was the benefit score (unaided - aided) for the 25-item HHIE. Randomization: Participants were stratified into one of three hearing loss categories based on better-ear PTA4: normal (≤ 20 dB HL), mild (20.1-35 dB HL), or moderate (35.1-50 dB HL). The random assignment of sequential enrollees within each hearing loss category to the three treatment groups made use of a site-specific pregenerated randomization list produced from a random-numbers table. Blinding: It was not possible to blind the participants as to the fitting method used, but the research personnel assessing the outcomes were blinded to the treatment group.</p><p><strong>Results: </strong>Numbers randomized: The 584 enrollees were randomized to one of the three treatment groups: AB (<i>n</i> = 190), CD (<i>n</i> = 193), and EF (<i>n</i> = 201).</p><p><p>Trial status: The trial began on November 1, 2020, and 6-month outcomes were obtained from the last participant on March 29, 2024. Numbers analyzed: At the 6-week measurement interval, outcome measures were completed for 182 AB, 172 CD, and 178 EF participants, representing 91.1% of the 584 individuals who enrolled. At the 6-month interval, completed outcomes were available for 166 AB, 148 CD, and 151 participants, representing 79.6% of the 584 original enrollees. Outcome: Bootstrapped (<i>N</i> = 1,000) means and 95% confidence intervals (CIs) at 6 weeks were 16.4 (95% CI [14.3, 18.7]), 16.8 (95% CI [14.9, 18.6]), and 15.2 (95% CI [13.5, 17.1]) for the AB, CD, and EF treatment groups on the primary outcome measure (PHAB global). At 6 months, primary outcome scores were 15.5 (95% CI [13.4, 17.8]), 16.3 (95% CI [14.4, 18.2]), and 15.3 (95% CI [13.5, 17.3]) for the AB, CD, and EF treatment groups, respectively. At both measurement intervals, there were no significant effects of treatment group (<i>p</i> > .05) for the primary or secondary outcome measures. Harms: No significant adverse events or side effects were observed.</p><p><strong>Conclusions: </strong>At both the 6-week and 6-month postfit intervals, each of the two self-fit methods (CD, EF) yielded outcomes (primary and secondary) that were noninferior to the professional-fit best-practices (AB) fitting method. In addition, on average, clinically meaningful benefit was provided regardless of the fitting method.</p><p><strong>Supplemental material: </strong>https://doi.org/10.23641/asha.28585145.</p>","PeriodicalId":51254,"journal":{"name":"Journal of Speech Language and Hearing Research","volume":" ","pages":"1-24"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Speech Language and Hearing Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1044/2024_JSLHR-24-00423","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"AUDIOLOGY & SPEECH-LANGUAGE PATHOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
试验设计:这是一项随机多地点非劣效性比较临床试验,有三个平行分支,比较听力学家验配的最佳实践方法和两种实验性自我验配(个人验配)方法。结果在验配后 6 周和 6 个月进行测量:参与者:五百八十四名参与者符合以下纳入标准并注册:(a) 年龄在 50 至 79 岁之间;(b) 以前从未使用或试用过助听器;(c) 能说英语、阅读英语和理解英语;(d) 愿意以 650 美元/对的价格购买助听器;(e) 没有记忆或认知障碍诊断;(f) 25 项老年人听力障碍量表 (HHIE) 评分大于 4 分;(g) 蒙特利尔认知评估评分≥ 23 分;(h) 没有因特定听力标准而被排除在外。基于气导纯音阈值的听力排除标准如下:(a) 双耳所有频率(250-8000 Hz)的阈值均小于 20 dB HL(无听力损失);(b) 较好耳 500、1000、2000 和 4000 Hz 的纯音平均值(PTA4)> 50 dB HL(中度以上听力损失);(c) 三个或三个以上频率的耳间差> 20 dB 或 500 或 1000 Hz 的耳间差≥ 40 dB。干预措施:三组接受相同的助听器,由听力学家采用最佳方法(AB 组)或自己采用两种有效的自我验配方法之一进行验配(CD 和 EF 组)。目标:假设 CD 和 EF 两种自我验配方法的效果均不逊于专业验配方法 AB。结果:主要结果指标是助听器益处档案(PHAB)的总体得分,次要结果指标是 25 项 HHIE 的益处得分(无助听-有助听)。随机分组:根据较好耳部 PTA4 将参与者分为三个听力损失类别:正常(≤ 20 dB HL)、轻度(20.1-35 dB HL)或中度(35.1-50 dB HL)。使用随机数字表中预先生成的特定地点随机列表,将每个听力损失类别中的连续参试者随机分配到三个治疗组。盲法:无法对参与者使用的验配方法进行盲测,但评估结果的研究人员对治疗组进行了盲测:随机数字:584 名参加者被随机分配到三个治疗组中的一组:AB组(n = 190)、CD组(n = 193)和EF组(n = 201):试验于 2020 年 11 月 1 日开始,2024 年 3 月 29 日从最后一名参与者处获得 6 个月的结果。分析人数在 6 周测量间隔期,182 名 AB 型、172 名 CD 型和 178 名 EF 型参与者完成了结果测量,占 584 名注册者的 91.1%。在 6 个月的测量间隔中,166 名 AB 型参与者、148 名 CD 型参与者和 151 名 EF 型参与者完成了结果测量,占 584 名原始注册者的 79.6%。结果:6周时,AB、CD和EF治疗组在主要结果测量(PHAB总分)上的引导平均值(N = 1,000)和95%置信区间(CIs)分别为16.4(95% CI [14.3,18.7])、16.8(95% CI [14.9,18.6])和15.2(95% CI [13.5,17.1])。6 个月时,AB、CD 和 EF 治疗组的主要结果得分分别为 15.5(95% CI [13.4,17.8])、16.3(95% CI [14.4,18.2])和 15.3(95% CI [13.5,17.3])。在两次测量间隔中,治疗组对主要或次要结果测量均无显著影响(P > .05)。危害:未观察到明显的不良事件或副作用:在配戴后 6 周和 6 个月的时间间隔内,两种自我配戴方法(CD、EF)所产生的结果(主要结果和次要结果)均不劣于专业配戴的最佳实践(AB)配戴方法。此外,无论采用哪种拟合方法,平均都能获得有临床意义的益处。补充材料:https://doi.org/10.23641/asha.28585145。
A Multisite Randomized Controlled Trial Comparing the Effectiveness of Two Self-Fit Methods to the Best-Practices Method of Hearing Aid Fitting.
Trial design: This is a randomized multisite noninferiority comparative-effectiveness clinical trial with three parallel branches comparing a best-practices audiologist-fit method to two experimental self-fit (person-fit) methods. Outcomes were measured at 6 weeks and 6 months post-fit.
Method: Participants: Five hundred eighty-four participants met the following inclusion criteria and enrolled: (a) age between 50 and 79 years; (b) never used or tried hearing aids previously; (c) can speak, read, and understand English well; (d) willing to purchase the study hearing aids for $650/pair; (e) no diagnosis of a memory or cognitive impairment; (f) 25-item Hearing Handicap Inventory for the Elderly (HHIE) score > 4; (g) Montreal Cognitive Assessment score ≥ 23; and (h) not excluded due to specific audiometric criteria. The audiometric exclusion criteria, based on air-conduction pure-tone thresholds, were as follows: (a) thresholds at all frequencies (250-8000 Hz) < 20 dB HL, for both ears (no hearing loss); (b) pure-tone average for 500, 1000, 2000, and 4000 Hz (PTA4) in the better ear > 50 dB HL (greater than moderate hearing loss); and (c) interaural difference > 20 dB at three or more frequencies or ≥ 40 dB at 500 or 1000 Hz. Interventions: Three groups received the same hearing aids fitted either by an audiologist using best practices (Group AB) or by themselves using one of two efficacious self-fit methods (Groups CD and EF). Objectives: The effectiveness of each of the self-fit methods, CD and EF, was hypothesized to be noninferior to the professional-fit method, AB. Outcomes: The primary outcome measure was the global score from the Profile of Hearing Aid Benefit (PHAB), and the secondary outcome measure was the benefit score (unaided - aided) for the 25-item HHIE. Randomization: Participants were stratified into one of three hearing loss categories based on better-ear PTA4: normal (≤ 20 dB HL), mild (20.1-35 dB HL), or moderate (35.1-50 dB HL). The random assignment of sequential enrollees within each hearing loss category to the three treatment groups made use of a site-specific pregenerated randomization list produced from a random-numbers table. Blinding: It was not possible to blind the participants as to the fitting method used, but the research personnel assessing the outcomes were blinded to the treatment group.
Results: Numbers randomized: The 584 enrollees were randomized to one of the three treatment groups: AB (n = 190), CD (n = 193), and EF (n = 201).
Trial status: The trial began on November 1, 2020, and 6-month outcomes were obtained from the last participant on March 29, 2024. Numbers analyzed: At the 6-week measurement interval, outcome measures were completed for 182 AB, 172 CD, and 178 EF participants, representing 91.1% of the 584 individuals who enrolled. At the 6-month interval, completed outcomes were available for 166 AB, 148 CD, and 151 participants, representing 79.6% of the 584 original enrollees. Outcome: Bootstrapped (N = 1,000) means and 95% confidence intervals (CIs) at 6 weeks were 16.4 (95% CI [14.3, 18.7]), 16.8 (95% CI [14.9, 18.6]), and 15.2 (95% CI [13.5, 17.1]) for the AB, CD, and EF treatment groups on the primary outcome measure (PHAB global). At 6 months, primary outcome scores were 15.5 (95% CI [13.4, 17.8]), 16.3 (95% CI [14.4, 18.2]), and 15.3 (95% CI [13.5, 17.3]) for the AB, CD, and EF treatment groups, respectively. At both measurement intervals, there were no significant effects of treatment group (p > .05) for the primary or secondary outcome measures. Harms: No significant adverse events or side effects were observed.
Conclusions: At both the 6-week and 6-month postfit intervals, each of the two self-fit methods (CD, EF) yielded outcomes (primary and secondary) that were noninferior to the professional-fit best-practices (AB) fitting method. In addition, on average, clinically meaningful benefit was provided regardless of the fitting method.
期刊介绍:
Mission: JSLHR publishes peer-reviewed research and other scholarly articles on the normal and disordered processes in speech, language, hearing, and related areas such as cognition, oral-motor function, and swallowing. The journal is an international outlet for both basic research on communication processes and clinical research pertaining to screening, diagnosis, and management of communication disorders as well as the etiologies and characteristics of these disorders. JSLHR seeks to advance evidence-based practice by disseminating the results of new studies as well as providing a forum for critical reviews and meta-analyses of previously published work.
Scope: The broad field of communication sciences and disorders, including speech production and perception; anatomy and physiology of speech and voice; genetics, biomechanics, and other basic sciences pertaining to human communication; mastication and swallowing; speech disorders; voice disorders; development of speech, language, or hearing in children; normal language processes; language disorders; disorders of hearing and balance; psychoacoustics; and anatomy and physiology of hearing.